- Home
- CGAU vs TARS Comparison
CGAU vs TARS Comparison
Compare CGAU & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGAU | TARS |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CGAU | TARS |
|---|---|---|
| Price | $13.38 | $80.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $14.17 | ★ $76.56 |
| AVG Volume (30 Days) | ★ 824.1K | 376.9K |
| Earning Date | 10-28-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | ★ 236.39 | N/A |
| EPS | ★ 1.60 | N/A |
| Revenue | ★ $1,285,392,000.00 | $366,100,000.00 |
| Revenue This Year | $14.70 | $147.24 |
| Revenue Next Year | $12.63 | $53.11 |
| P/E Ratio | $8.38 | ★ N/A |
| Revenue Growth | 2.66 | ★ 182.44 |
| 52 Week Low | $5.41 | $38.51 |
| 52 Week High | $13.52 | $85.25 |
Technical Indicators
Market Signals| Indicator | CGAU | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 65.98 | 59.02 |
| Support Level | $13.08 | $77.44 |
| Resistance Level | $13.52 | $82.90 |
| Average True Range (ATR) | 0.42 | 3.43 |
| MACD | 0.05 | -0.18 |
| Stochastic Oscillator | 94.04 | 53.07 |
Price Performance
Historical ComparisonAbout CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.